Stefan Mauss

Summary

Publications

  1. ncbi L-Carnitine in the treatment of HIV-associated lipodystrophy syndrome
    S Mauss
    Specialized practice for HIV and Hepatogastroenterology, Duesseldorf, Germany
    HIV Med 2:59-60. 2001
  2. ncbi Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, 40237 Duesseldorf, Germany
    J Hepatol 44:S114-8. 2006
  3. ncbi HCV/HIV-coinfection--is there a state of the art after APRICOT and RIBAVIC?
    S Mauss
    Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, 40237 Duesseldorf, Germany
    J Antimicrob Chemother 56:615-8. 2005
  4. ncbi [Progress in the treatment of hepatitis B and C co-infection in HIV patients]
    S Mauss
    Zentrum für HIV und Hepatogastroenterologie, Dusseldorf
    MMW Fortschr Med 146:27-9. 2004
  5. ncbi A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Dusseldorf, Germany
    Hepatology 40:120-4. 2004
  6. ncbi A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir
    S Mauss
    Center for HIV and Hepatogastroenterology, Duesseldorf, Germany
    HIV Med 5:15-7. 2004
  7. doi Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Duesseldorf, Germany
    J Hepatol 55:1235-40. 2011
  8. ncbi Clinical implications of resistance patterns against HBV-polymerase inhibitors for the treatment of chronic hepatitis B
    Stefan Mauss
    Center for HIV and Gastroenterology, Dusseldorf, Germany
    J HIV Ther 12:92-4. 2007
  9. ncbi Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Dusseldorf, Germany
    AIDS 18:F21-5. 2004
  10. ncbi Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Duesseldorf, Germany
    Hepatology 59:46-8. 2014

Detail Information

Publications33

  1. ncbi L-Carnitine in the treatment of HIV-associated lipodystrophy syndrome
    S Mauss
    Specialized practice for HIV and Hepatogastroenterology, Duesseldorf, Germany
    HIV Med 2:59-60. 2001
    ..These preliminary data do not support the use of L-carnitine for the rapid reversal of advanced fat tissue alterations due to HIV-associated lipodystrophy...
  2. ncbi Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, 40237 Duesseldorf, Germany
    J Hepatol 44:S114-8. 2006
    ..Adverse events specific to the HCV/HIV-patient population as compared to HCV-mono-infected patients are the occurrence of hyperlactataemia/lactic acidosis and hepatic decompensation...
  3. ncbi HCV/HIV-coinfection--is there a state of the art after APRICOT and RIBAVIC?
    S Mauss
    Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, 40237 Duesseldorf, Germany
    J Antimicrob Chemother 56:615-8. 2005
    ..The use of higher ribavirin doses and longer treatment periods should be systematically studied to improve hepatitis C therapy in coinfected patients in the near future...
  4. ncbi [Progress in the treatment of hepatitis B and C co-infection in HIV patients]
    S Mauss
    Zentrum für HIV und Hepatogastroenterologie, Dusseldorf
    MMW Fortschr Med 146:27-9. 2004
    ..In patients with markers of advanced liver cirrhosis a substantial risk for the development of hepatic decompensation under interferon-based therapy was observed. Antiretroviral therapy with didanosine may further enhance this risk...
  5. ncbi A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Dusseldorf, Germany
    Hepatology 40:120-4. 2004
    ..Patients discontinuing therapy due to noncompliance or request did so early, thereby limiting the cost of an unsuccessful approach to treatment...
  6. ncbi A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir
    S Mauss
    Center for HIV and Hepatogastroenterology, Duesseldorf, Germany
    HIV Med 5:15-7. 2004
    ..In conclusion, gastrointestinal tolerance of a regimen containing an increased dose of ritonavir 200 mg bid was low, while the regimen did not prevent a decrease of amprenavir and possibly lopinavir plasma concentrations...
  7. doi Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Duesseldorf, Germany
    J Hepatol 55:1235-40. 2011
    ..To assess renal function more accurately in the normal range, we used the recently validated, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula to calculate the estimated glomerular filtration rate (eGFR)...
  8. ncbi Clinical implications of resistance patterns against HBV-polymerase inhibitors for the treatment of chronic hepatitis B
    Stefan Mauss
    Center for HIV and Gastroenterology, Dusseldorf, Germany
    J HIV Ther 12:92-4. 2007
  9. ncbi Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Dusseldorf, Germany
    AIDS 18:F21-5. 2004
    ..This paper identifies risk factors associated with hepatic decompensation in APRICOT...
  10. ncbi Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Duesseldorf, Germany
    Hepatology 59:46-8. 2014
    ..In addition to being a safety concern, substantial ribavirin dose reductions have to be considered in these patients, as anemia was more pronounced in patients with impaired renal function...
  11. ncbi Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection
    Guenther Schmutz
    Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, 40237 Duesseldorf, Germany
    AIDS 20:1951-4. 2006
    ..It is unknown to date whether combination therapy with lamivudine plus tenofovir could be superior to sequential therapy with tenofovir after the occurrence of lamivudine resistance...
  12. ncbi Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Duesseldorf, Germany
    Antivir Ther 13:1091-5. 2008
    ..Broad use of tenofovir and an ageing HIV- infected population have created an interest in renal function in HIV patients. Serum cystatin C is a newer marker of renal function and might be more sensitive than creatinine...
  13. ncbi Management and therapy of chronic hepatitis C virus infection in HIV-infected individuals
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, 40237 Duesseldorf, Germany
    J HIV Ther 12:11-7. 2007
    ....
  14. ncbi Antiretroviral therapy with tenofovir is associated with mild renal dysfunction
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Duesseldorf, Germany
    AIDS 19:93-5. 2005
    ..In total, 24 patients on tenofovir versus five control patients had proteinuria greater than 130 mg/day. In the majority of patients on tenofovir proteinuria was of tubular origin...
  15. doi Treatment of chronic hepatitis B and the implications of viral resistance to therapy
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, 40237 Duesseldorf, Germany
    Expert Rev Anti Infect Ther 6:191-9. 2008
    ..Suggestions for avoiding resistance and management of established drug resistance are provided for each individual approved compound...
  16. ncbi HIV-associated and antiretroviral-induced hyperlipidaemia: an update
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, D 40237 Duesseldorf, Germany
    J HIV Ther 8:29-31. 2003
    ..Given the overall low number of cardiovascular events, an individualised approach seems adequate...
  17. doi Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients
    Christian Korner
    Department of Internal Medicine I, University of Bonn, Germany, Sigmund Freud Str 25, Bonn 53127, Germany
    Clin Sci (Lond) 116:861-70. 2009
    ..The results of the present study suggest that HCV co-infection sensitizes CD4+ T-cells towards apoptosis in untreated HIV-positive patients. However, this effect is rapidly lost under effective antiretroviral therapy...
  18. doi Drug-drug interactions in the treatment of HCV among people who inject drugs
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Dusseldorf, Germany
    Clin Infect Dis 57:S125-8. 2013
    ..In addition to highlighting relevant drug-drug interactions, alternative drugs that can be safely used are suggested. ..
  19. ncbi Differentiating hyperlipidaemia associated with antiretroviral therapy
    Stefan Mauss
    Center for HIV and Hepatogastroenterology, Duesseldorf, Germany
    AIDS 17:189-94. 2003
    ..Hyperlipidaemia associated with antiretroviral treatment has led to concerns for an increased cardiovascular risk in HIV-infected patients...
  20. ncbi Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir
    Julie A Sheldon
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 19:2036-8. 2005
    ....
  21. ncbi Care of patients with hepatitis C and HIV co-infection
    Vincent Soriano
    AIDS 18:1-12. 2004
  22. doi Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 22:1399-410. 2008
    ..The present study represents an update of the current knowledge about HBV/HIV coinfection and an intent to provide practical advise about how to give the best care to HIV-infected persons with chronic hepatitis B...
  23. ncbi Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients
    Jürgen Kurt Rockstroh
    Department of Medicine I, University of Bonn, Germany
    AIDS 16:2083-5. 2002
    ..In HIV/HCV-co-infected patients, the therapeutic benefit of high-dose IFN-alpha therefore seems to be limited by its poor tolerability...
  24. ncbi Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients
    Esther Voigt
    University of Bonn, Bonn, Germany
    J Infect 53:36-42. 2006
    ..Therefore, treatment options for chronic hepatitis C in HIV-coinfected patients need to be evaluated...
  25. ncbi Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine
    Stefan Mauss
    AIDS 19:101-2. 2005
  26. ncbi Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    AIDS 21:1073-89. 2007
  27. ncbi Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel
    Vincent Soriano
    AIDS 16:813-28. 2002
  28. ncbi Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir?
    Stefan Mauss
    AIDS 16:296-7. 2002
  29. pmc Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
    Christoph Wyen
    Department of Internal Medicine, University of Cologne, Koln, Germany
    J Antimicrob Chemother 61:914-8. 2008
    ..The aim of this study was to investigate the frequency of CYP2B6 polymorphisms (according to ethnicity) and the influence of heterozygosity and homozygosity on plasma concentrations of efavirenz and nevirapine...
  30. ncbi Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir
    Julie Sheldon
    Hospital Carlos Ill, Madrid, Spain
    Antivir Ther 10:727-34. 2005
    ..The aim of this study was to analyse the HBV polymerase (pol) from HIV/HBV-coinfected patients with detectable serum levels of HBV DNA during treatment with TDF for longer than 6 months...
  31. ncbi Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine
    Ulrich A Walker
    Medizinische Universitatsklinik, Department of Clinical Immunology, Freiburg, Germany
    Hepatology 39:311-7. 2004
    ..Moderate mtDNA depletion in liver does not necessarily lead to hyperlactatemia, but more pronounced decreases in hepatic mtDNA may be an important contributor to lactate elevation...
  32. ncbi Rapid development of central adiposity after postexposure prophylaxis with antiretroviral drugs: a proof of principle?
    Stefan Mauss
    AIDS 17:944-5. 2003
  33. ncbi Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection
    Florian van Bömmel
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charite, Universitatsmedizin Berlin, Campus Virchow, Berlin, Germany
    Hepatology 40:1421-5. 2004
    ..In conclusion, tenofovir may become an effective alternative for the treatment of patients with lamivudine-resistant HBV infection...